iBio, Inc. Common Stock
IBIOiBio, Inc. is a biotechnology company that specializes in the development and production of plant-based biopharmaceutical products. Using proprietary plant-based expression systems, the company focuses on creating vaccines, monoclonal antibodies, and other therapeutic proteins. iBio aims to leverage its technology to provide cost-effective and scalable solutions for the development of biologics and vaccines.
Company News
iBio, Inc. (NASDAQ: IBIO) announced a private placement financing of approximately $26 million led by Frazier Life Sciences. The company will use proceeds to advance preclinical cardiometabolic programs including IBIO-610 and IBIO-600, extending cash runway into calendar 2028. The offering is expected to close on January 13, 2026.
iBio, an AI-driven biotechnology company, will present at the Guggenheim Healthcare Innovation Conference in Boston, discussing its development of precision antibody therapies for obesity and cardiometabolic diseases.
iBio and AstralBio have developed a novel amylin receptor agonist antibody that significantly reduced acute food intake in a mouse model of obesity, comparable to a leading amylin peptide agonist. The findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiom...
iBio has in-licensed a potentially best-in-class long-acting anti-myostatin antibody from AstralBio and is launching a new program featuring a myostatin + activin A bispecific antibody designed to promote weight loss, prevent muscle loss and weight regain.
The biopharmaceuticals contract manufacturing market is expected to grow at a steady CAGR due to the increasing prevalence of chronic diseases, growing R&D investments in biologics and biosimilars, and the rise in outsourcing by biopharma giants to streamline drug development.
